Orion Portfolio Solutions LLC Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Orion Portfolio Solutions LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 692.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 28,181 shares of the medical device company’s stock after buying an additional 24,624 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in DexCom were worth $2,192,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Forvis Mazars Wealth Advisors LLC boosted its holdings in DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after acquiring an additional 118 shares in the last quarter. Principal Securities Inc. lifted its position in shares of DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after purchasing an additional 135 shares during the period. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. TD Private Client Wealth LLC increased its position in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after buying an additional 167 shares during the period. Finally, GPS Wealth Strategies Group LLC raised its stake in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after buying an additional 185 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Down 1.4 %

NASDAQ:DXCM opened at $67.32 on Wednesday. The company has a market cap of $26.31 billion, a PE ratio of 47.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a 50 day simple moving average of $81.62 and a two-hundred day simple moving average of $77.11. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $141.99.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last quarter. 0.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have weighed in on the company. Cfra Research raised DexCom to a “hold” rating in a research report on Friday, March 21st. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Canaccord Genuity Group lifted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.